On July 30, 2025 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported the launch of NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company’s PanTracer portfolio (Press release, NeoGenomics Laboratories, JUL 30, 2025, View Source [SID1234654659]). PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The launch of our liquid biopsy test positions us at the forefront of the precision oncology market," said Tony Zook, Chief Executive Officer, NeoGenomics. "As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It’s a strategic milestone that underscores our commitment to sustainable growth and clinical leadership."
Using circulating tumor DNA (ctDNA) from a simple blood draw, PanTracer LBx provides access to biomarker information when tissue samples are insufficient or unavailable. The test is designed to offer a seven-day turnaround time and analyze over 500 genes, including MSI and bTMB, to deliver timely, actionable insights. When indicated, it can be ordered as a standalone option, as a reflex when tissue testing fails, or concurrently with tissue analysis. Clinical applications include therapy selection, trial matching, and longitudinal monitoring.
PanTracer LBx strengthens NeoGenomics’ pan-solid tumor CGP portfolio, working seamlessly with tissue-based options like PanTracer Tissue, providing a testing strategy across a range of solid cancers. Complemented by a broad portfolio of testing services and dedicated clinical support, the launch expands NeoGenomics’ position in the growing $3–5 billion liquid biopsy market and advances its goal of delivering deep insights to more patients across diverse care settings.